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ABSTRACT
Chronic kidney disease (CKD) in recipients of myeloablative (MA) allogeneic hematopoietic cell transplantation
(HCT) has been well characterized. However, the risk of CKD after HCT using reduced-intensity conditioning
(RIC) is not well known. We compared the incidence of CKD by conditioning regimen in 221 allogeneic HCT
recipients (MA5 117, RIC5 104) who had survived for$1 year post-HCT and had no history of CKDpretrans-
plant. CKD was defined as glomerular filtration rate (GFR)\60 mL/min/1.73 m2 for $3 months anytime after
180 days post-HCT. The median follow-up was 28 months (range: 12-75) for MA and 25 months (range: 12-67)
for the RIC group. The 3-year cumulative incidence rate of CKD was 28% (95% confidence intervals [CI],
19%-36%) inMA and 29% (95%CI, 20%-38%) in the RIC group (P5 .44). Inmultivariate analysis, conditioning
regimen intensity had no impact on the risk of developing CKD (relative risk [RR] for MA 1.50 [95% CI,
0.78-2.89] versus the RIC regimen). Factors independently associated with an increased risk of CKDwere older
age at transplant, acute graft-versus-host disease, cyclosporine use for.6months, and acute kidney injury in the
early posttransplant period. CKD is frequent in long-term adult allogeneic HCT survivors, but RIC is associated
with similar risks as MA conditioning. Continuous monitoring of renal function is necessary in allogeneic HCT
survivors, and studies exploring prevention strategies are needed.
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Chronic kidney disease (CKD) affects 15%-40%
of adult survivors of myeloablative (MA) allogeneic he-
matopoietic cell transplantation (HCT) [1-4]. Previ-
ous reports have described multiple clinical CKD
syndromes in long-term survivors ofMAHCT includ-
ing progressive acute kidney injury (AKI) [1,5], ne-
phrotic syndrome [6], and renal failure secondary to
thrombotic microangiopathy [7]. Total body irradia-
tion (TBI) and preparative regimen chemotherapy,
graft-versus-host disease (GVHD), and use of calci-
neurin inhibitors have been implicated as risk factors
for CKD [1,2,8-10]. Allogeneic HCT using reduced-
intensity conditioning (RIC), which utilizes lower
doses of chemotherapy with or without TBI, is being
increasingly used for patients who cannot tolerate the658toxicities of an MA regimen [11]. RIC regimens have
been reported to be associated with lower treatment-
related mortality, and may have lower morbidity com-
pared to MA regimens [12]. However, the incidence
and risk factors of CKD in survivors of RIC HCT
have not been well described. We conducted a retro-
spective cohort study of long-term adult allogeneic
HCT survivors to compare the incidence and risk fac-




Consecutive patients who underwent an allogeneic
HCT using either MA or RIC regimens between
CKD in MA and RIC Allogeneic HCT 659January 2000 and 2005 at the University of Minnesota
were included in this study if: (1) they were $18 years
of age at the time of HCT, (2) had survived at least
1 year posttransplant, and (3) had normal renal function
at the time of HCT. Patients with multiple myeloma
(MM) (N 5 5) or history of CKD (N 5 3) prior to
transplantation were excluded from this analysis. Pa-
tients were considered for RIC HCT if they were not
eligible for transplantation using an MA regimen, ei-
ther because of older age (.55 years for related donors
and.45 years for unrelated donors), significant comor-
bidities, or extensive prior therapy. Transplant-related
and outcome data were retrieved from the University
of Minnesota Blood and Marrow Transplant Program
Database, which prospectively collects these data on
all patients transplanted at our institution. Additional
data for this study were abstracted from patient medical
records. Patients were treated according to clinical
protocols approved by our institutional review board.
All patients are routinely followed up at our trans-
plant program at scheduled intervals (100 days, and 6,
9, 12, 18, and 24 months) until at least 2 years after
transplantation. They are seen more frequently within
or after the first 2 years, as clinically indicated at the
discretion of their transplant physician. All creatinine
levels included in this study were measured at our hos-
pital laboratory.
Conditioning Regimen
MA and RIC regimens used at our institution have
been described previously [13-17]. Briefly, patients un-
dergoing MA HCT received a regimen consisting of
TBI and cyclophosphamide (Cy) with or without flu-
darabine (Flu). RIC regimens consisted of TBI with ei-
ther Cy and Flu or busulfan (Bu) and cladribine (Clad).
The TBI dose inMA regimens was 1320 cGy (165 cGy
twice daily 4 days) and in RIC regimens was 200 cGy
(single fraction), and was given without kidney shield-
ing. Our GVHD prophylaxis and treatment regimens
have also been described previously [13,15,17,18]. All
patients received GVHD prophylaxis with cyclospor-
ine (CSA) (days 23 to at least 1100), with trough
levels maintained between 200 and 400 ng/mL and ei-
ther methotrexate (MTX) or mycophenolate mofetil
(MMF).
Study Definitions
CKD was defined according to the National Kid-
ney Foundation guidelines as a glomerular filtration
rate (GFR) of\60 mL/min/1.73 m2 for 3 months or
more [19]. GFR was estimated using the Modification
of Diet in Renal Disease (MDRD) equation (GFR
[mL/min/1.73 m2] 5 186  [serum creatinine]21.154
 [age] 20.203  [0.742 if female]  [1.210 if African
American]) [20]. CKD after HCT was defined as per-
sistent decrease in GFR for at least 3 months anytimeafter 180 days posttransplant. The first occasion when
a decrease in GFR was noted was considered as the
time of onset of CKD. A .50% decrease in GFR
compared to baseline within the first 6 months post-
HCT was classified as AKI [21].
Patients with the following diagnoses were classi-
fied as having low-risk disease: acute leukemia in first
complete remission, chronic myelogenous leukemia
(CML) in first chronic phase, myelodysplastic syn-
drome (MDS), and nonmalignant hematologic dis-
eases; high-risk disease included all other diagnoses.
HCT comorbidity index (HCT-ci) scores, as de-
scribed by Sorror et al. [22], were retrospectively as-
signed to all patients and were categorized as low
(score 0), intermediate (score 1-2), or high (score$3).
Statistical Analysis
Comparison of patient and transplant characteris-
tics betweenMA and RIC groups was performed using
chi-square, Fisher’s exact, or Wilcoxon’s rank sum
test, as appropriate [23]. The cumulative incidence of
CKD was calculated by treating deaths from any cause
as a competing risk [24].
Cox regression analysis was performed to evaluate
potential risk factors for CKD. In addition to condi-
tioning regimen intensity (MA versus RIC), variables
considered in the multivariate model included age,
ethnicity (white versus other), sex (male versus female),
any smoking history pre-HCT (yes versus no), history
of hypertension or diabetes pre-HCT (yes versus no),
body mass index at HCT (\25 kg/m2 versus 25-29.9
kg/m2 versus $30 kg/m2), HCT-ci score at HCT
(low versus intermediate versus high), donor type (re-
lated versus unrelated), AKI within first 6 months
post-HCT (none versus moderate versus severe), use
of CSA for .6 months (yes versus no), grade II-IV
acute GVHD (aGVHD) (yes versus no), and chronic
GVHD (cGVHD) (yes versus no). Because all patients
included in this study had survived for at least 1 year,
aGVHD and cGVHD were considered as categoric
instead of time-dependent variables. Use of CSA for
.6 months, aGVHD and cGVHD were not signifi-
cantly correlated; hence, all 3 variables were included
in the risk-factor analysis. The multivariate models
were adjusted for time since HCT and for baseline
GFR.
Event times weremeasured from date of transplan-
tation to date of death or last contact. All P-values were
2 sided. Analyses were performed using SAS 9.1 soft-
ware (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Study eligibility criteria were met by 221 patients
(MA 5 117, RIC 5 104). Patient- and transplant-re-
lated characteristics of the 2 groups are described in
660 A. Al-Hazzouri et al.Table 1. MA HCT recipients were younger at HCT
(median age 38 versus 54 years, P \ .01), were less
likely to be obese (13% versus 29%, P 5 .01), were
less likely to have a prior history of hypertension (7%
versus 22%, P\ .01), and were more likely to receive
a matched related donor graft (53% versus 42%, P 5
.01). MA HCT recipients also had a higher baseline
GFR (median 112 versus 96 mL/min/1.73 m2, P \
.01). The 2 groups were otherwise comparable with re-
spect to prevalence of diabetes mellitus and history of





(N 5 104) P-value
Median age at HCT
(range), years
38 (19-59) 54 (19-69) \.01
Sex 1.00
Male 72 (62%) 64 (62%)
Female 45 (38%) 40 (38%)
Smoker .34
Yes 31 (27%) 37 (36%)
No 85 (73%) 66 (63%)
Missing 1 (1%) 1 (1%)
Hypertension pre-HCT \.01
Yes 8 (7%) 23 (22%)
No 109 (93%) 81 (78%)
Diabetes mellitus pre-HCT .23
Yes 5 (4%) 9 (9%)
No 112 (96%) 95 (91%)
BMI at HCT .01
#24.9 kg/m2 52 (44%) 36 (35%)
25-29.9 kg/m2 50 (43%) 38 (37%)
$30 kg/m2 15 (13%) 30 (29%)
Median baseline GFR
(range), mL/min/1.73m2
112 (64-218) 96 (66-183) \.01
HCT-ci score at HCT .39
Low 36 (31%) 25 (24%)
Intermediate 42 (36%) 36 (35%)
High 39 (33%) 43 (41%)
Diagnosis \.01
Acute leukemia/MDS 69 (59%) 43 (41%)
Chronic leukemia 20 (17%) 7 (7%)
Lymphoma 17 (15%) 34 (33%)
Other 11 (9%) 20 (19%)
Disease status at HCT .30
Standard risk 61 (52%) 47 (45%)
High risk 56 (48%) 57 (55%)
Donor type .01
Related donor 62 (53%) 42 (40%)
Unrelated donor 17 (15%) 8 (8%)
Umbilical cord blood 38 (32%) 54 (52%)
AKI within first 6 months 102 (87%) 85 (82%) .33
CSA use .6 months 50 (43%) 36 (35%) .22
Acute grade 2-4 GVHD 56 (48%) 61 (59%) .11
Chronic GVHD 56 (49%) 48 (46%) .80
Median follow-up (range),
months
28 (12-75) 25 (12-67) .01
MA indicates myeloablative; RIC, reduced-intensity conditioning;
HCT, hematopoietic cell transplantation; BMI, bodymass index;
HCT-ci, hematopoietic cell transplantation specific comorbidity
index; MDS, myelodysplastic syndrome; AKI, acute kidney in-
jury; GFR, glomerular filtration rate; CSA, cyclosporine;
GVHD, graft-versus-host diseasesmoking prior to HCT, HCT-ci scores, disease status
at HCT, duration of CSA use, and rates of posttrans-
plant AKI, aGVHD, and cGVHD. None of the pa-
tients received an autologous HCT prior to their
allogeneic HCT. MA conditioning regimens included
Cy/TBI (N 5 39) or Cy/Flu/TBI (N 5 78). RIC reg-
imens consisted of Cy/Flu/TBI (N 5 99) or Bu/Clad/
TBI (N 5 5). Median follow-up duration was 28
months (range: 12-75 months) for the MA and 25
months (range: 12-67 months) for the RIC groups.
For these 1-year survivors, overall survival (OS) at 2
years posttransplant was 89% for MA and 77% for
RIC recipients.
Incidence of CKD
Overall, 60 patients developed CKD with a 3-year
cumulative incidence rate of 29% (95% confidence in-
tervals [CI], 22%-35%). These included 30 patients
each from the 2 cohorts, resulting in a 3-year cumula-
tive incidence rate of 28% (95% CI, 19%-36%) in the
MA and 29% (95% CI, 20%-38%) in the RIC groups
(P5 .44) (Figure 1). The median time from transplant
to development of CKD was 11 months (range: 6-29
months) and 9 months (range: 6-18 months), respec-
tively. Among patients who developed CKD, 75%
did so within 1 year of transplantation. Late-onset
CKD, with onset .1 year after HCT, was more prev-
alent in the MA group (N 5 11) compared to the RIC
group (N5 4). Severe CKD (GFR\30 mL/min/1.73
m2) developed in 2 patients, with 1 requiring hemodi-
alysis. Among the remaining patients with moderate
CKD (GFR 30-59 mL/min/1.73 m2) (N 5 58), only
2 had progression to end-stage renal disease (ESRD)
requiring hemodialysis at a median follow up of 22
months (range: 1-53months) from the onset of chronic
renal impairment.
The most common syndrome encountered in pa-
tients developing CKD was that of nonresolving AKI
with a continued decrease inGFR (N5 45). Late-onset
CKD because of multiorgan failure and medications
Figure 1. Cumulative incidence of CKD after allogeneic HCT.
CKD in MA and RIC Allogeneic HCT 661was seen in 13 patients. Thrombotic microangiopathy
was the cause of late-onset CKD in 2 patients.
We also analyzed the change in GFR within the
first year posttransplant. For our cohort, who had
survived for at least 1-year posttransplant, a similar
decrease in GFR was noted for both MA and RIC
recipients (Figure 2).
Risk Factors for CKD
In multivariate analysis, conditioning regimen in-
tensity had no impact on the risk of developing CKD
(relative risk [RR] for MA regimen, 1.50 [95% CI,
0.78-2.89] versus RIC regimen) (Table 2). Factors in-
dependently associated with an increased risk of CKD
in 1-year survivors of allogeneic HCT were age at
transplantation, AKI within first 6 months post-
HCT, grade II-IV GVHD and CSA use for .6
months. The risk factors for developing CKD were
the same as for the whole cohort on subgroup analyses
limited to each conditioning regimen, except for age,
which was not predictive for CKD in recipients of
MA conditioning.
DISCUSSION
We report a relatively high but comparable inci-
dence of late-onset CKD in long-term survivors of
MAandRICHCT.The advantage of using less intense
doses of chemotherapy and TBI in conditioning is po-
tentially offset by the typical older age and presence of
comorbidities in recipients of RICHCT.Also, risk fac-
Figure 2. Change in glomerular filtration rate (GFR) among mye-
loablative (N5 117) and reduced-intensity (N5 104) allogeneic he-
matopoietic cell transplant recipients over time. All patients included
in this study had survived for at least 1 year or more after transplan-
tation. Each box-plot represents the range of GFR observed; the
ends of the boxes represent the 25th and 75th percentiles, the bars
indicate the 10th and 90th percentiles, and the line shows the
median.tors independent of conditioning regimen intensity,
such as aGVHD and use of CSA, have an important
role in the development of CKD. A global decline in
GFR occurs early posttransplant irrespective of condi-
tioning regimen intensity with incomplete recovery by
1 year. CKDdevelops relatively early after transplanta-
tion, and typically is the result of continued decrease in
GFR following an early posttransplant renal insult.
Only 1 other study has systematically investigated
the incidence and risk factors of CKD after RIC
HCT. Weiss et al. [2], in a retrospective cohort study
of 122 nonmyeloablative HCT recipients, reported
development of CKD in 66% patients at 1 year post-
transplant. Although the MDRD equation was used
to calculate GFR, CKD was defined as reduction in
GFR by 25% or greater compared to baseline, and in-
cluded patients who survived for 6 months post-HCT.
This more liberal definition of CKDmay have overes-
timated the incidence of CKD in their cohort, because
75% of a normal GFR may not lead to serious or pro-
gressive CKD. Nevertheless, their study highlights the
problem of CKD in survivors of RIC HCT. They
reported that acute renal injury, previous autologous
HCT, long-term calcineurin inhibitor use, and exten-
sive cGVHD were independently associated with
CKD.
A significant predictor for CKD was AKI in the
early posttransplant period. AKI is a well described
risk factor for CKD despite the various definitions
used [1,2,25,26]. Both the MA and RIC cohorts in
our study had similar frequency of AKI. aGVHD
was an independent risk factor for CKD in our analy-
sis. T cell-mediated inflammation of the renal paren-
chyma, systemic cytokine release, and nephrotoxicity
Table 2. Risk Factors Predicting Chronic Kidney Disease after Allogeneic
Hematopoietic Cell Transplantation




Age (each year increase) 1.03 (1.00-1.06) 0.05
AKI within first 6 months
No† 1.00 0.02
Yes 4.03 (1.22-13.27)
Acute grade II-IV GVHD
No† 1.00 0.02
Yes 2.01 (1.12-3.61)
CSA use .6 months
No† 1.00 \0.01
Yes 3.49 (1.97-6.18)
RR inicates relative risk; CKD, chronic kidney disease; CI, confi-
dence interval; RIC, reduced-intensity conditioning; MA, mye-
loablative conditioning; AKI, acute kidney injury; GFR,
glomerular filtration rate; GVHD, graft-versus-host disease;
CSA, cyclosporine.
*Adjusted for time since transplant and baseline GFR.
†Indicates reference value.
662 A. Al-Hazzouri et al.of calcineurin inhibitors are etiologies of GVHD-re-
lated CKD. These mechanisms are involved in both
aGVHD and cGVHD [2,27].We did not find an asso-
ciation between cGVHD and CKD. Patients with
cGVHD are also more likely to have had previous
aGVHD, and tend to be exposed to CSA for a longer
period of time, and these risk factors might be more
important than cGVHD in the pathogenesis of
HCT-associated CKD. CSA nephrotoxicity can result
from direct toxicity, hemodynamic disturbances in the
renal vasculature [28], or microangiopathy secondary
to the procoagulant effect of GVHD-mediated tumor
necrosis factor release [29]. TBI has been postulated to
be an important risk factor for CKD in HCT recipi-
ents [30,31]. However, we did not observe a difference
in the risk of developing CKD among recipients of
high-dose (MA) and low-dose (RIC) TBI. In a large
retrospective cohort study of 1635 patients, Hingorani
et al. [1] also did not find TBI to be an independent
predictor of CKD.
Our study has certain limitations. Smoking has
been reported to be an important risk factor for
CKD [32,33]. Given the retrospective nature of our
study, smoking history was recorded as an affirmative
variable only, because the quantity of smoking could
not be obtained reliably. Although regularly moni-
tored and adjusted for clinical management, variations
of CSA serum concentration could also have an impact
on the risk of CKD, and were not accounted for in our
study. The follow-up of our cohort is relatively short
for a study investigating late effects of transplantation.
However, CKD developed within the first year in the
majority of patients with a subsequent plateau in its
cumulative incidence, and the onset of CKD beyond
3 years is uncommon in this and other reported series.
In conclusion, CKD is frequent in long-term adult
allogeneic HCT survivors. RIC is associated with
similar risks of CKD as MA conditioning. Older age,
AKI, aGVHD, and prolonged CSA exposure increases
the risk of CKD. Continuous attention to even a mod-
est decline in renal function is necessary in allogeneic
HCT survivors, and studies exploring prevention
strategies to limit progression to ESRD are needed.
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